PJP
Invesco Pharmaceuticals ETF
The Invesco Dynamic Pharmaceuticals Portfolio ETF tracks an index of US pharmaceutical companies selected and weighted based on various fundamental and risk factors.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 583.9 M
ASSETS UNDER MGMT
58 bp
EXPENSES
Fund Basics
| Inception date | Jun 23, 2005 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 6.1 % |
| GILEAD SCIENCES INC | 6.1 % |
| ABBVIE INC | 5.9 % |
| PFIZER INC | 5.7 % |
| AMGEN INC | 5.6 % |
| JOHNSON & JOHNSON | 5.3 % |
| MERCK & CO. INC. | 5.1 % |
| ABBOTT LABORATORIES | 4.9 % |
| AMNEAL PHARMACEUTICALS, INC. CLASS A | 3.6 % |
| UNITED THERAPEUTICS CORP | 3.5 % |
Constituent Breakdown
| Number of holdings | 31 |
| Herfindahl-Hirschman Index | 417 |
| Wgt avg mkt cap (mns) | $197,625 |
| Large cap (>$10bn) | 65.7% |
| Mid cap ($2-10bn) | 23.7% |
| Small cap (<$2bn) | 10.5% |
| Developed mkts. | 100.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 94.1 % |
 |
IRELAND | 5.8 % |
Historical Performance
Standardized Performance (as of 10/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 24.9% | 34.7% | 22.9% | 23.7% | 10.5% | 8.8% | 10.4% | 10.7% |
| Dividend Yield | 1.0% | 1.4% | 1.4% | 1.3% | 1.1% | 1.0% | 1.4% | 1.3% |
| Total Returns | 25.9% | 36.1% | 24.2% | 25.0% | 11.7% | 9.8% | 11.8% | 12.0% | Ann. Volatility | 18.0% | 17.6% | 18.0% | 16.4% | 16.6% | 18.4% | 19.3% | 19.0% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.40 | 8% |
| MSCI EAFE | 0.46 | 17% |
| MSCI Emg Mkts | 0.11 | 2% |
Liquidity Measures
| Avg. volume (000) | 38 |
| ADV traded (mns) | $5 |
| Turnover | 0.9% |
| Avg. Bid/Ask (% of price) | 0.11% |
Technical Indicators
| 30d moving avg. (EMA) | $126.29 |
| Relative strength (RSI) | 52 |
| MACD/Signal | 1.13/0.99 |
| Bollinger Bands (Upper/Lower) | $131.50/$121.21 |
| Short interest (% of AUM) | 1.7% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PJP |
Expenses vs. PJP |
ALTAR Score™ vs. PJP |
|---|---|---|---|---|
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 56.6% | +2 bp | -1.4% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 40.2% | -45 bp | -1.1% |
| MEDX | Horizon Kinetics Medical ETF | 39.4% | +27 bp | -5.7% |
| IYH | iShares U.S. Healthcare ETF | 38.9% | -21 bp | -1.7% |
| XLV | Health Care Select Sector SPDR | 38.7% | -50 bp | -1.0% |
| FHLC | Fidelity MSCI Health Care Index ETF | 37.3% | -50 bp | -2.1% |
| VHT | Vanguard Health Care ETF | 37.2% | -49 bp | -2.2% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 36.8% | -23 bp | -7.8% |
| THNR | Amplify Weight Loss Drug & Treatment ETF | 36.8% | +1 bp | -2.7% |
| IHE | iShares U.S. Pharmaceuticals ETF | 36.2% | -21 bp | -1.8% |
Risk and Returns: PJP vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/14/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.9%
ALTAR SCORE™
75th
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 1,440 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. PJP's ALTAR Score™ is approximately 0.7 standard
deviations above the category average. This places PJP in the 75th percentile
among funds in the category.
Sell-Side Consensus
$149.19
PRICE TARGET
+13.9%
UPSIDE